MAIA Biotechnology, Inc. Retained Earnings
MAIA Biotechnology, Inc. (MAIA) had Retained Earnings of -$123.94 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$123.94M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$116.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$109.63M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$106.00M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$123.94M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$116.00M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$109.63M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | -$106.00M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | -$97.10M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$91.75M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | -$87.23M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$83.66M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$80.93M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | -$72.05M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$63.98M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$57.72M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$52.85M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$48.32M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | -$44.21M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$40.06M 10-Q/A · filed 2023-02-06 | -$39.09M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$35.16M 10-Q · filed 2022-08-22 | |
| 2021-12-31 | -$28.44M 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |